ATAI Life Sciences NV
NASDAQ:ATAI
ATAI Life Sciences NV
NASDAQ:ATAI
Price:
1.39 USD
-6.08%
Market Closed
Updated:
Jun 10, 2024
P/B
Price to Book Value
Price to Book Value
1
Current
1.7
Median
2
Industry
Lower
than median
Lower
than industry value
Price to Book Value (P/B) ratio is a valuation multiple that measures the market's valuation of a company relative to its book value. The P/B ratio is only considered useful in practice when applied to capital-intensive businesses.
P/B
=1
Market Cap
/
231.1m
Book Value of Equity
222.5m
All Countries
| Market Cap | P/B | ||||
|---|---|---|---|---|---|
| DE |
|
ATAI Life Sciences NV
NASDAQ:ATAI
|
231.1m USD | 1 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -21 763 099 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
807.8B USD | 63.1 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
4.4T DKK | 44.4 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 583.1 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
354B USD | 5.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
330.9B USD | 8.2 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
194.6B GBP | 6.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
193.4B CHF | 6.6 | |
| CH |
|
Novartis AG
SIX:NOVN
|
185.8B CHF | 5.2 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
162B USD | 1.8 |
P/B Forward Multiples
Forward P/B multiple is a version of the P/B ratio that uses forecasted equity for the P/B calculation. 1-Year, 2-Years, and 3-Years forwards use equity forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/B
N/A
2-Years Forward
P/B
N/A
3-Years Forward
P/B
N/A
You don't have any saved screeners yet
